There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bausch + Lomb Corporation (BLCO – Research Report) and Edgewise Therapeutics (EWTX – Research Report) with bullish sentiments.
Bausch + Lomb Corporation (BLCO)
RBC Capital analyst Douglas Miehm assigned a Buy rating to Bausch + Lomb Corporation today and set a price target of $18.00. The company’s shares closed last Friday at $14.64, close to its 52-week low of $13.62.
According to TipRanks.com, Miehm is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bausch + Lomb Corporation with a $19.29 average price target, implying a 34.7% upside from current levels. In a report issued on April 7, Citi also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Edgewise Therapeutics (EWTX)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Edgewise Therapeutics today and set a price target of $32.00. The company’s shares closed last Friday at $15.23.
According to TipRanks.com, Timashev is a 3-star analyst with an average return of
Edgewise Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $35.33, which is a 131.5% upside from current levels. In a report issued on April 16, Wedbush also maintained a Buy rating on the stock with a $26.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BLCO:
- Bausch + Lomb Announces Q1 2024 Financial Results
- Bausch ‘win’ in Xifaxan case clears major hurdle ahead of spin, says Jefferies
- Bausch suit creates added uncertainty on B+L spin, says TD Cowen
- Jefferies sees more upside for Bausch Health if Xifaxan ruling positive
- Bausch + Lomb Reveals Eye Health Innovations
